baculoviru
express
vector
system
bev
far
new
thirti
year
research
use
platform
express
recombin
protein
thousand
protein
success
express
purifi
howev
much
time
bev
releg
rank
research
tool
seen
last
decad
elev
bev
research
tool
establish
manufactur
platform
product
novel
biolog
product
ten
year
ago
two
commerci
product
manufactur
use
bev
manufactur
platform
veterinari
vaccin
prevent
classic
swine
fever
pig
sinc
seven
new
product
licens
four
human
includ
vaccin
therapeut
mani
product
develop
tabl
pass
tip
point
product
becom
mainstream
bev
platform
activ
util
major
player
biotechnolog
industri
develop
new
product
although
bev
platform
distinct
featur
make
attract
platform
product
mani
biolog
ideal
suit
product
factor
protein
complex
modif
scale
cost
must
consid
collect
select
manufactur
platform
extens
review
elsewher
review
explor
bev
platform
look
system
work
advantag
limit
platform
manufactur
regulatori
perspect
opportun
develop
new
product
use
bev
abund
review
latest
develop
gene
therapi
influenza
vaccin
field
exampl
final
consid
newer
area
product
show
promis
futur
bev
platform
previous
describ
platform
take
advantag
baculovirus
natur
propens
infect
insect
cell
natur
differ
type
baculovirus
host
rang
restrict
invertebr
laboratori
manufactur
purpos
commonli
use
baculoviru
autographa
californica
nuclear
polyhedrosi
viru
acmnpv
viru
dna
genom
approxim
kb
larg
size
genom
give
baculoviru
ampl
capac
accommod
larg
amount
foreign
dna
includ
multipl
gene
advantag
express
vector
vaccinia
adenoviru
begin
bev
process
recombin
baculoviru
construct
compris
desir
gene
interest
goi
fig
first
goi
clone
transfer
plasmid
typic
behind
strong
polyhedrin
promot
drive
protein
express
high
level
insect
cell
notabl
promot
activ
e
coli
therefor
stabl
express
cassett
goi
flank
acmnpv
dna
eg
polyhedrin
promot
one
side
portion
essenti
gene
insect
cell
mixtur
transfer
plasmid
parent
acmnpv
dna
linear
parent
polyhedrin
gene
portion
miss
render
plasmid
parent
dna
undergo
homolog
recombin
gener
de
novo
recombin
baculovirus
baculovirus
plate
individu
plaqu
purifi
isol
singl
pure
plaqu
recombin
baculoviru
plaqu
subsequ
passag
multipl
round
insect
cell
infect
gener
stock
establish
work
viru
bank
wvb
util
protein
product
manufactur
purpos
import
wvb
stabl
retain
integr
viru
passag
scale
laboratori
kit
life
technolog
employ
bacmid
technolog
develop
allow
research
quickli
easili
construct
recombin
baculovirus
e
coli
rather
homolog
recombin
insect
cell
tool
use
research
purpos
howev
recombin
gene
cassett
baculovirus
inher
unstabl
may
easili
lost
viru
passag
stabil
baculoviru
import
consider
protein
product
envis
wvb
establish
use
infect
insect
cell
stimul
protein
product
cell
seed
cultur
flask
product
bioreactor
product
wvb
ad
infect
insect
cell
logarithm
growth
phase
baculovirus
reprogram
cellular
machineri
produc
recombin
protein
follow
protein
express
typic
hour
cell
andor
supernat
harvest
depend
whether
product
intracellular
secret
respect
protein
purifi
accord
standard
techniqu
ultracentrifug
column
chromatographi
mani
differ
insect
cell
line
use
bev
common
deriv
ovarian
cell
fall
armi
worm
spodoptera
frugiperda
eg
protein
scienc
corpor
cabbag
looper
trichoplusia
ni
high
cell
life
technolog
high
five
cell
use
manufactur
licens
human
papillomaviru
vaccin
glaxosmithklin
cell
use
produc
antigen
use
prostat
cancer
immunotherapi
dendreon
expressf
cell
use
manufactur
three
licens
product
influenza
vaccin
protein
scienc
corpor
gene
therapi
treatment
famili
lipoprotein
lipas
defici
uniqur
ingelvac
veterinari
vaccin
protect
porcin
circoviru
type
boehring
ingelheim
vetmedica
larg
scale
manufactur
commerci
product
requir
specif
cell
line
characterist
scalabl
high
yield
abil
grow
media
qualif
meet
regulatori
agenc
eg
fda
ema
etc
requir
puriti
safeti
bev
employ
recombin
technolog
give
research
product
develop
level
control
product
process
possibl
techniqu
good
exampl
found
vaccin
manufactur
tradit
vaccin
made
cultiv
larg
volum
pathogen
protect
desir
gener
raw
materi
requir
product
accomplish
infect
substrat
embryon
chicken
egg
mammalian
cell
use
manufactur
major
vaccin
recommend
routin
immun
pathogen
either
weaken
administ
live
live
attenu
vaccin
kill
inactiv
reagent
formalin
heat
prior
formul
vaccin
method
yield
safe
effect
vaccin
howev
import
shortcom
observ
first
concern
specif
exampl
tradit
influenza
vaccin
product
involv
viru
propag
egg
influenza
virus
rna
virus
tendenc
mutat
optim
growth
gener
chang
introduc
viru
sequenc
littl
impact
vaccin
efficaci
howev
sinc
viru
receptor
bird
mammal
differ
chang
meaning
document
case
chang
render
influenza
vaccin
ineffect
bev
process
involv
pathogen
growth
therefor
avoid
complic
rather
cultiv
pathogen
collect
raw
materi
recombin
baculoviru
construct
code
antigen
requir
protect
sinc
accommod
growth
need
made
antigen
exact
sequenc
match
human
pathogen
potenti
solv
ineffect
observ
vaccin
describ
skowronski
et
al
moreov
specif
point
mutat
introduc
enhanc
featur
stabil
exampl
recent
report
purifi
hemagglutinin
protein
protect
antigen
influenza
vaccin
appear
unstabl
srid
potenc
assay
due
specif
cystein
residu
protein
mutat
cystein
residu
residu
possibl
prevent
enhanc
stabil
second
shortcom
tradit
vaccin
manufactur
process
length
influenza
serv
good
exampl
influenza
epidem
occur
everi
year
annual
influenza
vaccin
recommend
center
diseas
control
prevent
addit
pandem
outbreak
occur
occasion
recent
swine
flu
timeli
vaccin
manufactur
critic
ensur
adequ
vaccin
suppli
avail
influenza
vaccin
manufactur
take
averag
six
month
process
creat
seed
viru
slow
mean
manufactur
season
influenza
vaccin
must
begin
winter
prior
epidem
season
strain
preval
definit
known
guarante
adequ
suppli
result
season
avail
influenza
vaccin
match
circul
influenza
strain
moreov
presid
council
advisor
scienc
technolog
pcast
report
pandem
influenza
vaccin
readili
avail
pandem
peak
major
concern
public
health
safeti
pcast
identifi
recombin
technolog
freedom
viru
growth
egg
adapt
solut
problem
influenza
vaccin
requir
seed
virus
produc
littl
day
addit
specif
speed
recombin
technolog
offer
advantag
respect
puriti
product
design
respect
puriti
recombin
product
free
pathogen
egg
mani
chemic
formalin
antibiot
undesir
allergen
product
design
recombin
techniqu
make
possibl
engin
protein
desir
featur
fusion
protein
increas
immunogen
includ
multipl
antigen
truncat
protein
delet
domain
improv
yield
eas
purif
one
exampl
applic
antigen
use
proveng
immunotherapi
antigen
fusion
glycoprotein
consist
prostat
acid
phosphatas
pap
link
factor
use
stimul
autolog
antigen
present
cell
activ
antigen
present
cell
enhanc
cell
viabil
pap
serv
target
antigen
anoth
exampl
vaccin
manufactur
glaxosmithklin
vaccin
bival
particl
vlp
compris
human
papillomaviru
protein
strain
express
truncat
protein
manufactur
abl
prevent
intracellular
vlp
would
complic
purif
instead
subunit
protein
purifi
high
degre
vlp
assembl
achiev
vitro
bev
platform
inher
safeti
measur
built
attract
regulatori
perspect
baculovirus
narrow
host
rang
restrict
specif
insect
consid
safe
use
biolog
pesticid
neg
impact
plant
mammal
bird
fish
insect
peopl
expos
baculovirus
daili
consum
fresh
veget
instanc
serv
coleslaw
may
contain
hundr
million
baculovirus
baculoviru
vector
also
explor
gene
therapi
vector
studi
demonstr
baculovirus
replic
mammalian
cell
express
gene
cassett
unless
driven
mammalian
promot
major
consider
regulatori
agenc
evalu
novel
cell
substrat
potenti
harbor
adventiti
agent
could
threaten
patient
safeti
adventiti
agent
replic
insect
mammalian
cell
notabl
except
arbovirus
transmit
human
via
insect
bite
caus
complic
enceph
hemorrhag
fever
mitig
risk
cell
insect
fall
armyworm
cabbag
looper
use
bev
note
nonetheless
adventiti
agent
detect
insect
cell
line
instanc
trichoplusia
ni
high
five
cell
line
use
make
found
latent
infect
alphanodaviru
induc
recombin
baculoviru
infect
addit
insect
cell
line
gener
drosophila
melanogast
shown
harbor
innat
retroel
deriv
retrovirus
could
potenti
infecti
recent
possibl
viru
identifi
spodoptera
frugiperda
cell
although
studi
show
viru
could
enter
replic
human
cell
line
therefor
unlik
risk
novel
cell
line
like
need
character
monitor
presenc
viru
nodavirus
retrovirus
other
gener
adventiti
agent
potenti
threat
cell
substrat
origin
includ
insect
other
must
thoroughli
test
presenc
infect
agent
allow
regulatori
agenc
manufactur
use
addit
safeti
consider
discuss
two
import
regulatori
featur
associ
bev
platform
consid
first
bev
transient
protein
express
system
recombin
baculovirus
use
vari
base
foreign
gene
cassett
singl
cell
line
use
express
protein
fig
qualifi
cell
line
small
feat
take
year
work
adequ
ensur
puriti
safeti
addit
high
product
stabl
cell
line
independ
qualifi
time
genet
composit
chang
contrast
cell
line
use
bev
transient
express
system
remain
constant
consequ
need
qualifi
second
featur
grow
number
product
approv
regulatori
agenc
worldwid
tabl
case
technolog
prior
regulatori
approv
remov
barrier
futur
product
approv
technolog
becom
mainstream
less
novel
approv
safeti
databas
patient
administ
product
without
complic
continu
grow
nine
product
licens
provid
regul
confid
platform
follow
characterist
make
bev
platform
appeal
commerci
manufactur
scalabl
biosafeti
flexibl
exist
manufactur
capac
insect
cell
grown
suspens
cell
baculovirus
optim
larg
scale
multipl
passag
cultur
size
limit
size
bioreactor
exampl
expressf
cell
use
produc
recombin
protein
scale
rang
two
l
cost
good
bev
product
larg
depend
capit
cost
yield
discuss
cox
vast
global
bioreactor
capac
l
alreadi
exist
present
opportun
minim
invest
need
establish
bev
manufactur
facil
moreov
opportun
yield
improv
abund
includ
genet
approach
describ
elsewher
unlik
product
facil
bev
facil
use
produc
varieti
product
especi
dispos
technolog
employ
singl
cell
line
use
product
differ
product
featur
especi
meaning
region
world
limit
manufactur
capac
exist
singl
bev
facil
could
exampl
use
produc
vaccin
diseas
endem
region
quickli
convert
produc
pandem
influenza
vaccin
emerg
final
bev
platform
requir
handl
live
potenti
danger
pathogen
requir
biocontain
costli
reduc
bev
platform
versatil
technolog
use
manufactur
mani
product
howev
platform
may
better
suit
product
certain
protein
instanc
small
protein
requir
modif
best
made
e
coli
quickli
gener
high
yield
low
cost
yeast
cerevisia
also
produc
high
yield
protein
low
cost
capabl
modif
insect
cell
capabl
mani
modif
protein
requir
complex
modif
fold
may
best
made
mammalian
express
system
exampl
glycosyl
pattern
produc
insect
mammalian
cell
relat
glycoprotein
produc
insect
cell
often
correctli
fold
biolog
activ
immunogen
howev
insect
cell
gener
less
complex
mammalian
cell
neg
impact
biolog
function
develop
made
address
limit
includ
engin
transgen
insect
cell
line
stabli
express
mammalian
glycosyl
enzym
enzym
gene
interest
singl
baculoviru
whether
requir
must
assess
protein
protein
basi
bev
approach
gene
therapi
larg
involv
product
recombin
virus
raav
hous
therapeut
dna
use
raav
gene
deliveri
vector
gain
popular
sever
reason
includ
gene
express
lack
pathogen
abil
transduc
wide
varieti
cell
divid
nine
differ
raav
serotyp
commonli
use
gene
therapi
serotyp
differ
propens
infect
infect
kinet
recombin
gene
therapi
develop
shown
promis
time
howev
major
limit
implement
inabl
scale
manufactur
process
produc
suffici
quantiti
raav
origin
raav
vector
produc
mammalian
tissu
cultur
use
adher
cell
cell
requir
flask
produc
enough
materi
larg
anim
studi
human
clinic
trial
raav
particl
overcom
limit
scientist
adopt
optim
bev
platform
product
larg
scale
high
titer
raav
adjust
paramet
multipl
infect
cell
densiti
ferment
mode
raav
yield
order
vector
genom
per
liter
report
tradit
bev
product
strategi
raav
requir
insect
cell
three
differ
recombin
baculovirus
express
major
aav
replic
enzym
express
aav
virion
coat
protein
express
gene
interest
flank
aav
invert
termin
repeat
element
requir
rescu
replic
packag
gene
adenoviru
helper
need
requir
mammalian
cell
raav
product
due
genet
instabl
construct
streamlin
system
develop
rep
cap
protein
express
singl
baculoviru
transcrib
singl
mrna
speci
enhanc
stabil
altern
genet
modif
made
origin
construct
enhanc
stabil
improv
express
import
regulatori
hurdl
overcom
glybera
receiv
market
author
europ
make
first
gene
therapi
product
approv
western
world
launch
bev
platform
spotlight
prefer
platform
raav
manufactur
glybera
alipogen
tiparvovec
compris
human
gene
raav
serotyp
vector
use
treatment
patient
lipoprotein
lipas
lpl
defici
clinic
studi
shown
glybera
safe
effect
glybera
like
begin
come
gene
therapi
approach
relev
estim
thousand
monogen
diseas
treatment
activ
investig
divers
array
therapeut
area
dozen
product
candid
clinic
develop
summar
tabl
hemophilia
one
area
progress
made
review
four
ongo
human
clinic
trial
involv
raav
serotyp
design
express
factor
ix
treatment
hemophilia
b
tabl
factor
viii
therapi
target
treatment
hemophilia
common
sever
inherit
bleed
disord
modest
increas
plasma
factor
viii
level
expect
requir
clinic
relev
treatment
retin
degener
includ
macular
degener
leber
congenit
amaurosi
type
anoth
area
intens
investig
retin
treatment
ideal
cell
access
intravitr
subretin
inject
abil
assess
structur
function
noninvas
serotyp
commonli
use
therapi
type
capabl
infect
photoreceptor
promin
cell
type
retin
degener
diseas
central
nervou
system
cn
parkinson
alzheim
diseas
also
activ
test
therapi
promis
aav
exhibit
strong
prefer
neuron
transduct
make
popular
gene
deliveri
vehicl
cn
therapi
vector
improv
still
need
optim
treatment
discuss
final
duchenn
muscular
dystrophi
dmd
therapeut
target
progress
made
although
singl
gene
affect
dmd
dystrophin
long
known
larg
size
made
gene
therapi
challeng
recent
treatment
approach
overcom
includ
deliveri
strategi
fifti
year
influenza
vaccin
manufactur
technolog
remain
larg
stagnant
chang
licensur
trival
vaccin
season
influenza
compos
recombin
hemagglutinin
ha
deriv
two
one
b
influenza
virus
select
inclus
annual
influenza
vaccin
world
health
organ
vaccin
licens
fda
adult
older
influenza
vaccin
standard
contain
specif
amount
ha
major
surfac
glycoprotein
influenza
viru
recombin
ha
form
trimer
turn
oligomer
immunogen
rosett
protein
purifi
high
level
result
vaccin
shown
safe
effect
clinic
studi
advantag
recombin
bev
vaccin
pandem
influenza
especi
import
vaccin
avian
influenza
virus
urgent
need
virus
high
pathogen
mortal
rate
human
fact
previous
demonstr
pandem
potenti
transmiss
monoval
variat
vaccin
call
develop
phase
ii
studi
schedul
vaccin
dose
ha
formul
adjuv
glucopyranosyl
lipid
astabl
emuls
glase
accept
safeti
reactogen
profil
elicit
serolog
respons
meet
seroconvers
criteria
adult
year
old
moreov
earlier
studi
show
peopl
administ
ahong
prime
enhanc
immun
respons
follow
administr
antigen
variant
vaccin
strain
liu
et
al
evalu
differ
subunit
vaccin
candid
show
protect
lethal
challeng
balbc
mice
specif
commerci
chicken
suggest
could
use
human
anim
vaccin
vlp
vaccin
pandem
influenza
develop
compos
recombin
ha
neuraminidas
na
matrix
protein
produc
cell
evalu
vlp
vaccin
phase
iii
studi
adult
year
old
show
two
dose
unadjuv
vaccin
hados
gener
result
seroconvers
similarli
phase
ii
studi
vlp
vaccin
adult
year
old
show
safe
dose
hados
elicit
high
rate
seroprotect
recent
vlp
vaccin
develop
compris
ha
na
protein
match
protein
match
vaccin
candid
test
without
iscomatrix
adjuv
balbc
mice
shown
protect
lethal
challeng
antibodi
ha
na
elicit
higher
respons
iscomatrix
group
although
data
promis
challeng
develop
vlp
vaccin
standard
vaccin
compon
eg
quantiti
ha
vs
na
vs
advantag
use
recombin
technolog
vaccin
design
opportun
modularli
add
subtract
antigen
formul
inclus
recombin
na
vlp
vaccin
shown
induc
format
antibodi
note
differ
vaccin
composit
eg
vlp
vs
subunit
vs
whole
virion
induc
differ
immun
profil
balbc
mice
advantag
variou
profil
yet
clear
flexibl
bev
platform
enabl
cater
toward
differ
output
besid
inclus
vlp
recombin
na
individu
produc
via
bev
may
serv
potenti
addit
influenza
vaccin
na
immun
reduc
infect
sever
durat
potenti
benefit
includ
recombin
na
influenza
vaccin
recent
review
opportun
emerg
bev
research
begin
pursuit
univers
influenza
vaccin
licens
influenza
vaccin
offer
limit
cross
protect
heterolog
influenza
virus
thu
need
annual
updat
season
influenza
vaccin
concern
pandem
prepared
success
univers
influenza
vaccin
would
offer
broad
protect
rang
differ
influenza
viru
strain
approach
univers
influenza
vaccin
design
includ
ha
construct
chimer
vaccin
compos
conserv
stalk
domain
fuse
exot
head
usual
avian
origin
approach
review
elsewher
bev
platform
base
recombin
technolog
offer
flexibl
genet
control
requir
design
manufactur
univers
vaccin
candid
review
taken
close
look
bev
platform
describ
platform
work
outlin
featur
limit
technolog
highlight
growth
opportun
emerg
two
recent
product
approv
expect
growth
continu
expand
futur
product
attain
regulatori
approv
approv
vaccin
broaden
accept
platform
beyond
initi
veterinari
border
use
healthi
adolesc
adult
human
therapeut
anoth
area
use
gene
therapi
particular
grow
area
interest
approv
glybera
drew
major
attent
raav
baculovirus
also
use
gene
deliveri
vector
recombin
protein
complex
produc
use
bev
explor
deliveri
variou
peptid
antigen
form
newli
character
vault
particl
speed
recombin
protein
produc
use
bev
make
particularli
attract
platform
design
safe
effect
vaccin
avail
time
combat
new
infecti
pathogen
aris
success
approach
demonstr
influenza
appli
broader
area
exampl
coronavirus
plagu
peopl
anim
especi
last
decad
lethal
outbreak
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
late
porcin
epidem
diarrhea
viru
pedv
coronavirus
share
similar
structur
includ
presenc
spike
glycoprotein
viral
envelop
domin
immunogen
multipl
coronaviru
vaccin
candid
develop
includ
recombin
spike
protein
either
alon
subunit
vaccin
togeth
recombin
envelop
membran
protein
vlp
demonstr
efficaci
anim
model
spike
protein
shown
immunogen
full
length
protein
truncat
protein
contain
extracellular
domain
multipl
rout
vaccin
administr
examin
two
recent
emerg
threat
chikungunya
viru
ebola
viru
address
vaccin
chikungunya
viru
caus
seriou
diseas
involv
sever
joint
pain
fatal
recent
outbreak
appear
saint
martin
decemb
sinc
made
way
countri
jurisdict
america
includ
continent
unit
state
chikungunya
arboviru
mani
opportun
develop
vaccin
review
subunit
vlp
vaccin
candid
express
chikungunya
viral
envelop
glycoprotein
develop
use
bev
vlp
demonstr
higher
immunogen
mice
ebola
viru
filoviru
caus
lethal
hemorrhag
fever
human
devast
africa
ongo
outbreak
ebola
viru
glycoprotein
shown
protect
antigen
could
produc
similar
chikungunya
viru
vaccin
addit
vaccin
bev
platform
shown
earli
promis
product
vaccin
exampl
heavi
chain
domain
clostridi
botulinum
neurotoxin
highli
toxic
protein
caus
botul
produc
bev
demonstr
immunogen
challeng
protect
mice
recombin
toxin
vaccin
diseas
clostridium
difficil
could
also
possibl
conclus
bev
versatil
platform
whose
potenti
begin
realiz
technolog
offer
speed
flexibl
specif
safeti
use
singl
cell
line
manufactur
multipl
product
make
bev
attract
platform
adopt
bev
use
develop
wide
varieti
product
especi
well
suit
combat
rapidli
emerg
danger
pathogen
new
threat
continu
rise
tool
bev
offer
import
defens
rachael
felberbaum
hold
phd
molecular
cell
development
biolog
yale
univers
ba
psycholog
univers
pennsylvania
join
protein
scienc
corpor
manufactur
recombin
vaccin
serv
senior
director
busi
develop
previous
dr
felberbaum
director
corpor
commun
protein
scienc
manag
corpor
commun
protarga
inc
pharmaceut
compani
also
held
variou
research
posit
univers
verlag
gmbh
co
kgaa
weinheim
